{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:08:32Z","timestamp":1793747312924,"version":"4.6.1"},"reference-count":128,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Since 1991, the CDC has recommended screening for hepatitis B virus (HBV) infection in pregnancy and universal hepatitis B vaccination of all medically stable infants at birth, serving as a core strategy to prevent perinatal and postnatal infection and eliminate HBV transmission nationwide. On December 5, 2025, the Advisory Committee on Immunization Practices (ACIP) voted (1) among women who screen negative in pregnancy, parents decide, in consultation with providers, when or if to vaccinate their child for hepatitis B, and if not at birth, then aged no earlier than 2\u00a0months, and (2) consider collection of infant immune titers to guide decision-making for completing the vaccine series. We conducted a comprehensive review of the evidence on the safety, immunogenicity, efficacy, and effectiveness of the birth dose and a delayed first dose, and of the potential role of serology for clinical decision-making. We analyzed studies of the epidemiology of HBV infection, clinical trials, systematic reviews, vaccine safety from surveillance and clinical studies, and the potential impact of revised guidelines on individual and public health. We synthesized the history of ACIP recommendations and resulting trends in HBV incidence. The review found strong evidence for the safety and effectiveness of the birth dose, and no improvement in safety or effectiveness with a delayed first dose. We found no evidence to support the use of postvaccination serology. Infant vaccination has resulted in a 99% reduction in pediatric HBV infections; we found no evidence to support a change in vaccine recommendations but identified potential health consequences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2025-075783","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:01:51Z","timestamp":1770267711000},"source":"Crossref","is-referenced-by-count":5,"title":["Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit"],"prefix":"10.1542","volume":"157","author":[{"given":"Angela K.","family":"Ulrich","sequence":"first","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek F.","family":"Fleming","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory J.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Mehr","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney G.","family":"Redepenning","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J.","family":"Stoddart","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah E.","family":"Moat","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle P.","family":"Walensky","sequence":"additional","affiliation":[{"name":"2Division of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve M.","family":"Lackritz","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2026090101164190000_r1","article-title":"Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP)","author":"CDC","year":"1991"},{"key":"2026090101164190000_r2","article-title":"Viral Hepatitis National Strategic Plan | HHS.Gov. Page","author":"HHS","year":"2016"},{"issue":"1337","key":"2026090101164190000_r3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1098\/rspb.1993.0102","article-title":"The influence of age on the development of the hepatitis B carrier state","volume":"253","author":"Edmunds","year":"1993","journal-title":"Proc Biol Sci."},{"issue":"1","key":"2026090101164190000_r4","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1186\/s12889-024-20462-4","article-title":"Global, regional, and national total burden related to hepatitis B in children and adolescents from 1990 to 2021","volume":"24","author":"Li","year":"2024","journal-title":"BMC Public Health."},{"issue":"8359","key":"2026090101164190000_r5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(83)90624-4","article-title":"Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine","volume":"2","author":"Beasley","year":"1983","journal-title":"Lancet."},{"key":"2026090101164190000_r6","doi-asserted-by":"crossref","DOI":"10.1542\/9781610025225","volume-title":"Red Book: 2021\u20132024 Report of the Committee on Infectious Diseases","author":"Kimberlin","year":"2021"},{"issue":"15","key":"2026090101164190000_r7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/jama.1995.03530150025029","article-title":"Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations","volume":"274","author":"Margolis","year":"1995","journal-title":"JAMA."},{"issue":"Suppl 1","key":"2026090101164190000_r8","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/jpids\/piu064","article-title":"Prevention of perinatal hepatitis B virus transmission","volume":"3","author":"Nelson","year":"2014","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"5","key":"2026090101164190000_r9","doi-asserted-by":"crossref","first-page":"e1141","DOI":"10.1542\/peds.2014-3213","article-title":"Outcomes of infants born to women infected with hepatitis B","volume":"135","author":"Schillie","year":"2015","journal-title":"Pediatrics."},{"issue":"3","key":"2026090101164190000_r10","doi-asserted-by":"crossref","first-page":"e20171870","DOI":"10.1542\/peds.2017-1870","article-title":"Elimination of perinatal hepatitis B: providing the first vaccine dose within 24\u00a0hours of birth","volume":"140","author":"Committee on Infectious Diseasescommittee on Fetus and Newborn","year":"2017","journal-title":"Pediatrics."},{"key":"2026090101164190000_r11","article-title":"Hepatitis B virus immunization in infants, children, and Adolescents - UpToDate","author":"Drutz","year":"2025"},{"issue":"1","key":"2026090101164190000_r12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of Hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep."},{"key":"2026090101164190000_r13","article-title":"ACIP Meeting Information","author":"CDC","year":"2025"},{"key":"2026090101164190000_r14","article-title":"Universal hepatitis B vaccination at birth: safety, effectiveness, and public health impact","author":"CIDRAP","year":"2025"},{"key":"2026090101164190000_r15","article-title":"The Advisory Committee on Immunization Practices (ACIP)","author":"Sekar","year":"2025"},{"key":"2026090101164190000_r16","article-title":"History and evolution of the Advisory Committee on Immunization Practices \u2014 United States, 1964\u20132014","author":"Smith","year":"2014"},{"key":"2026090101164190000_r17","article-title":"Grade Evidence Tables \u2013 Recommendations in MMWR","author":"CDC","year":"2025"},{"issue":"45","key":"2026090101164190000_r18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.15585\/mmwr.mm6745a4","article-title":"Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices","volume":"67","author":"Lee","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2026090101164190000_r19","article-title":"Evidence to recommendations frameworks","author":"CDC","year":"2025"},{"key":"2026090101164190000_r20","article-title":"Recombivax HB","author":"FDA","year":"2019"},{"key":"2026090101164190000_r21","author":"Engerix-B FDA","year":"2023"},{"issue":"5","key":"2026090101164190000_r22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1542\/peds.108.5.1123","article-title":"Childhood hepatitis B virus infections in the United States before hepatitis B immunization","volume":"108","author":"Armstrong","year":"2001","journal-title":"Pediatrics."},{"key":"2026090101164190000_r23","volume-title":"2022 Viral Hepatitis Surveillance Report","author":"CDC","year":"2024"},{"key":"2026090101164190000_r24","volume-title":"2023 Viral Hepatitis Surveillance Report","author":"CDC","year":"2025"},{"key":"2026090101164190000_r25","article-title":"Acute Hepatitis B among children and adolescents\u2014United States, 1990\u20132002","author":"CDC","year":"2004"},{"issue":"4","key":"2026090101164190000_r26","doi-asserted-by":"crossref","first-page":"e0118","DOI":"10.1097\/HC9.0000000000000118","article-title":"Prevalence and awareness of Hepatitis B virus infection in the United States: January 2017 - March 2020","volume":"7","author":"Bixler","year":"2023","journal-title":"Hepatol Commun."},{"key":"2026090101164190000_r27","article-title":"NNDSS Annual Summary Data 2016\u20132022 Request","author":"CDC","year":"2025"},{"issue":"361","key":"2026090101164190000_r28","first-page":"1","article-title":"Prevalence and trends in Hepatitis B virus infection in the United States, 2015\u20132018","author":"Kruszon-Moran","year":"2020","journal-title":"NCHS Data Brief."},{"issue":"2","key":"2026090101164190000_r29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.30831","article-title":"Chronic hepatitis B prevalence among foreign-born and U.S.-born adults in the United States, 1999\u20132016","volume":"71","author":"Le","year":"2020","journal-title":"Hepatology."},{"key":"2026090101164190000_r30","volume-title":"Advisory Committee on Immunization Practices (ACIP)","author":"CDC","year":"2025"},{"issue":"4","key":"2026090101164190000_r31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ajog.2014.10.1093","article-title":"Recent trends in hepatic diseases during pregnancy in the United States, 2002\u20132010","volume":"212","author":"Ellington","year":"2015","journal-title":"Am J Obstet Gynecol."},{"issue":"1","key":"2026090101164190000_r32","first-page":"4107329","article-title":"Hepatitis B virus testing and care among pregnant women using commercial claims data, United States, 2011\u20132014","volume":"2018","author":"Harris","year":"2018","journal-title":"Infect Dis Obstet Gynecol."},{"issue":"3","key":"2026090101164190000_r33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/0033354919836958","article-title":"Estimating annual births to hepatitis B surface antigen-positive women in the United States by using data on maternal country of birth","volume":"134","author":"Koneru","year":"2019","journal-title":"Public Health Rep."},{"issue":"1","key":"2026090101164190000_r34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/jwh.2011.2979","article-title":"Prevalence and temporal trends of hepatitis B, hepatitis C, and HIV\/AIDS co-infection during pregnancy across the decade, 1998\u20132007","volume":"21","author":"Salihu","year":"2012","journal-title":"J Womens Health (Larchmt)."},{"issue":"5","key":"2026090101164190000_r35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/0033354916663183","article-title":"Characteristics of pregnant women with hepatitis B virus infection in 5 US public health jurisdictions, 2008\u20132012","volume":"131","author":"Walker","year":"2016","journal-title":"Public Health Rep."},{"key":"2026090101164190000_r36","article-title":"Hepatitis B, Perinatal Infection 2017 Case Definition | CDC","author":"CDC","year":"2021"},{"issue":"2","key":"2026090101164190000_r37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/jpids\/piu115","article-title":"Estimated annual perinatal hepatitis B virus infections in the United States, 2000\u20132009","volume":"5","author":"Ko","year":"2016","journal-title":"J Pediatric Infect Dis Soc."},{"key":"2026090101164190000_r38","article-title":"Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data\u2014United States","author":"CDC","year":"2011"},{"issue":"5","key":"2026090101164190000_r39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2105\/AJPH.2008.136275","article-title":"Time for renewed commitment to viral hepatitis prevention","volume":"98","author":"Ward","year":"2008","journal-title":"Am J Public Health."},{"issue":"4","key":"2026090101164190000_r40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4269\/ajtmh.1995.53.419","article-title":"Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates","volume":"53","author":"Bassily","year":"1995","journal-title":"Am J Trop Med Hyg."},{"issue":"8","key":"2026090101164190000_r41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/00006454-200208000-00014","article-title":"Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age","volume":"21","author":"Greenberg","year":"2002","journal-title":"Pediatr Infect Dis J."},{"issue":"4","key":"2026090101164190000_r42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2017.11.079","article-title":"Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005\u20132015","volume":"36","author":"Haber","year":"2018","journal-title":"Vaccine."},{"issue":"13\u201314","key":"2026090101164190000_r43","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0264-410X(01)00518-7","article-title":"Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2\u00a0years","volume":"20","author":"Hieu","year":"2002","journal-title":"Vaccine."},{"issue":"11","key":"2026090101164190000_r44","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/00006454-200111000-00009","article-title":"Safety of neonatal hepatitis B vaccine administration","volume":"20","author":"Lewis","year":"2001","journal-title":"Pediatr Infect Dis J."},{"issue":"3","key":"2026090101164190000_r45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14760584.1.3.277","article-title":"Immunogenicity and reactogenicity of DTPw-HB\/Hib vaccine administered to colombian infants after a birth dose of hepatitis B vaccine","volume":"1","author":"L\u00f3pez","year":"2002","journal-title":"Expert Rev Vaccines."},{"issue":"12","key":"2026090101164190000_r46","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/archpedi.153.12.1279","article-title":"Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991\u20131998","volume":"153","author":"Niu","year":"1999","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"5","key":"2026090101164190000_r47","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/tropej\/fmm016","article-title":"Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study","volume":"53","author":"Sapru","year":"2007","journal-title":"J Trop Pediatr."},{"issue":"22","key":"2026090101164190000_r48","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.3748\/wjg.v13.i22.3084","article-title":"Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India","volume":"13","author":"Velu","year":"2007","journal-title":"World J Gastroenterol."},{"issue":"11","key":"2026090101164190000_r49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jamapediatrics.2018.2349","article-title":"Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial","volume":"172","author":"Wood","year":"2018","journal-title":"JAMA Pediatr."},{"issue":"6","key":"2026090101164190000_r50","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00006454-199706000-00009","article-title":"Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates","volume":"16","author":"Yerushalmi","year":"1997","journal-title":"Pediatr Infect Dis J."},{"issue":"1","key":"2026090101164190000_r51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/INF.0000000000001361","article-title":"Comparative efficacy, safety and immunogenicity of Hepavax-Gene TF and Engerix-B recombinant hepatitis B vaccines in neonates in China","volume":"36","author":"Zhu","year":"2017","journal-title":"Pediatr Infect Dis J."},{"issue":"3","key":"2026090101164190000_r52","doi-asserted-by":"crossref","first-page":"F206","DOI":"10.1136\/fn.81.3.F206","article-title":"Unexplained fever in neonates may be associated with hepatitis B vaccine","volume":"81","author":"Linder","year":"1999","journal-title":"Arch Dis Child Fetal Neonatal Ed."},{"key":"2026090101164190000_r53","volume-title":"Advisory Committee on Immunization Practices (ACIP)","author":"CDC","year":"2025"},{"issue":"7","key":"2026090101164190000_r54","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/01.inf.0000130953.08946.d0","article-title":"Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project","volume":"23","author":"Eriksen","year":"2004","journal-title":"Pediatr Infect Dis J."},{"issue":"3","key":"2026090101164190000_r55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2471\/BLT.24.291683","article-title":"Hepatitis B vaccination of preterm infants and risk of bronchopulmonary dysplasia: a cohort study, Australia","volume":"103","author":"Morgan","year":"2025","journal-title":"Bull World Health Organ."},{"issue":"9","key":"2026090101164190000_r56","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00006454-199609000-00007","article-title":"Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System","volume":"15","author":"Niu","year":"1996","journal-title":"Pediatr Infect Dis J."},{"issue":"5","key":"2026090101164190000_r57","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1542\/peds.112.5.1039","article-title":"Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases","volume":"112","author":"Verstraeten","year":"2003","journal-title":"Pediatrics."},{"key":"2026090101164190000_r58","first-page":"1665","article-title":"Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997\u20132002","volume-title":"J Toxicol Environ Health A.","author":"Gallagher","year":"2010"},{"issue":"1","key":"2026090101164190000_r59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2047-9158-2-25","article-title":"A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States","volume":"2","author":"Geier","year":"2013","journal-title":"Transl Neurodegener."},{"issue":"4","key":"2026090101164190000_r60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/toxics6040067","article-title":"Premature puberty and thimerosal-containing hepatitis B vaccination: a case-control study in the Vaccine Safety Datalink","volume":"6","author":"Geier","year":"2018","journal-title":"Toxics."},{"issue":"2","key":"2026090101164190000_r61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jegh.2015.06.002","article-title":"A longitudinal cohort study of the relationship between Thimerosal-containing hepatitis B vaccination and specific delays in development in the United States: assessment of attributable risk and lifetime care costs","volume":"6","author":"Geier","year":"2016","journal-title":"J Epidemiol Glob Health."},{"issue":"2","key":"2026090101164190000_r62","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1515\/intox-2015-0011","article-title":"Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study","volume":"8","author":"Geier","year":"2015","journal-title":"Interdiscip Toxicol."},{"key":"2026090101164190000_r63","volume-title":"Immunization Safety Review: Vaccines and Autism","author":"Immunization Safety Review IOM","year":"2004"},{"issue":"15\u201316","key":"2026090101164190000_r64","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0264-410X(00)00403-5","article-title":"A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity","volume":"19","author":"Nolan","year":"2001","journal-title":"Vaccine."},{"issue":"7537","key":"2026090101164190000_r65","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/bmj.38719.435833.7C","article-title":"Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis","volume":"332","author":"Lee","year":"2006","journal-title":"BMJ."},{"issue":"4","key":"2026090101164190000_r66","doi-asserted-by":"crossref","first-page":"ofx225","DOI":"10.1093\/ofid\/ofx225","article-title":"Comparative effectiveness of prophylactic strategies for perinatal transmission of hepatitis B virus: a network meta-analysis of randomized controlled trials","volume":"4","author":"Chen","year":"2017","journal-title":"Open Forum Infect Dis."},{"issue":"2","key":"2026090101164190000_r67","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0923-2516(97)89893-7","article-title":"Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine","volume":"148","author":"Da Villa","year":"1997","journal-title":"Res Virol."},{"issue":"1","key":"2026090101164190000_r68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jmv.1890410107","article-title":"Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes","volume":"41","author":"del Canho","year":"1993","journal-title":"J Med Virol."},{"issue":"6","key":"2026090101164190000_r69","doi-asserted-by":"crossref","first-page":"e1500","DOI":"10.1542\/peds.2013-2940","article-title":"Duration of protection after infant hepatitis B vaccination series","volume":"133","author":"Middleman","year":"2014","journal-title":"Pediatrics."},{"issue":"21","key":"2026090101164190000_r70","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.vaccine.2012.12.012","article-title":"Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review","volume":"31","author":"Schillie","year":"2013","journal-title":"Vaccine."},{"issue":"4","key":"2026090101164190000_r71","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/INF.0b013e31827bd1b0","article-title":"Determinants of Long-term protection after hepatitis B vaccination in infancy: a meta-analysis","volume":"32","author":"Sch\u00f6nberger","year":"2013","journal-title":"Pediatr Infect Dis J."},{"issue":"4","key":"2026090101164190000_r72","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/hep.32474","article-title":"Protection and antibody levels 35\u00a0years after primary series with hepatitis B vaccine and response to a booster dose","volume":"76","author":"Bruce","year":"2022","journal-title":"Hepatology."},{"issue":"1","key":"2026090101164190000_r73","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/jiv748","article-title":"Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose","volume":"214","author":"Bruce","year":"2016","journal-title":"J Infect Dis."},{"issue":"9","key":"2026090101164190000_r74","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1086\/606119","article-title":"Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose","volume":"200","author":"McMahon","year":"2009","journal-title":"J Infect Dis."},{"issue":"3A","key":"2026090101164190000_r75","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1016\/0002-9343(89)90525-1","article-title":"Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine","volume":"87","author":"Andr\u00e9","year":"1989","journal-title":"Am J Med."},{"issue":"5","key":"2026090101164190000_r76","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/infdis\/160.5.766","article-title":"Vaccination against hepatitis B: comparison of three different vaccination schedules","volume":"160","author":"Jilg","year":"1989","journal-title":"J Infect Dis."},{"issue":"8","key":"2026090101164190000_r77","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4161\/hv.24844","article-title":"Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand","volume":"9","author":"Poovorawan","year":"2013","journal-title":"Hum Vaccin Immunother."},{"issue":"10","key":"2026090101164190000_r78","doi-asserted-by":"crossref","first-page":"O680","DOI":"10.1111\/1469-0691.12591","article-title":"Hepatitis B immunity in teenagers vaccinated as infants: an Italian 17-year follow-up study","volume":"20","author":"Spada","year":"2014","journal-title":"Clin Microbiol Infect."},{"issue":"5","key":"2026090101164190000_r79","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1017\/ice.2015.6","article-title":"Response to challenge dose among young adults vaccinated for hepatitis B as infants: importance of detectable residual antibody to hepatitis B surface antigen","volume":"36","author":"Spradling","year":"2015","journal-title":"Infect Control Hosp Epidemiol."},{"issue":"2","key":"2026090101164190000_r80","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/infdis\/jiw142","article-title":"A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen","volume":"214","author":"Simons","year":"2016","journal-title":"J Infect Dis."},{"issue":"1","key":"2026090101164190000_r81","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41541-025-01188-9","article-title":"Level of antibody to hepatitis B surface antigen declined below 10\u2009mIU\/ml is still protective","volume":"10","author":"Shen","year":"2025","journal-title":"NPJ Vaccines."},{"issue":"6","key":"2026090101164190000_r82","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.4161\/hv.28480","article-title":"Immune memory to hepatitis B persists in children aged 7\u20138\u00a0years, who were vaccinated in infancy with 4 doses of Hexavalent DTPa-HBV-IPV\/Hib (Infanrix Hexa) vaccine","volume":"10","author":"Van Der Meeren","year":"2014","journal-title":"Hum Vaccin Immunother."},{"issue":"7364","key":"2026090101164190000_r83","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/bmj.325.7364.569","article-title":"Observational study of vaccine efficacy 14\u00a0years after trial of hepatitis B vaccination in Gambian children","volume":"325","author":"Whittle","year":"2002","journal-title":"BMJ."},{"issue":"3","key":"2026090101164190000_r84","doi-asserted-by":"crossref","first-page":"e58029","DOI":"10.1371\/journal.pone.0058029","article-title":"Observational study of vaccine efficacy 24\u00a0years after the start of Hepatitis B vaccination in two Gambian villages: No need for a booster dose","volume":"8","author":"Mendy","year":"2013","journal-title":"PLOS ONE."},{"key":"2026090101164190000_r85","article-title":"Vaccination coverage among young children (0\u201335\u00a0months)","author":"CDC","year":"2024"},{"issue":"6","key":"2026090101164190000_r86","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.acap.2024.04.003","article-title":"Racial and Ethnic Disparities in Attendance to Well-Child Visit Recommendations during COVID-19","volume":"24","author":"Abdus","year":"2024","journal-title":"Acad Pediatr."},{"issue":"3","key":"2026090101164190000_r87","doi-asserted-by":"crossref","first-page":"e20201823","DOI":"10.1542\/peds.2020-1823","article-title":"National Perinatal Hepatitis B Prevention Program: 2009\u20132017","volume":"147","author":"Koneru","year":"2021","journal-title":"Pediatrics."},{"issue":"2","key":"2026090101164190000_r88","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3201\/eid1202.050038","article-title":"Detecting hepatitis B surface antigen mutants - Volume 12, Number 2\u2014February 2006 - Emerging Infectious Diseases Journal - CDC","volume":"12","author":"Coleman","year":"2006","journal-title":"Emerging Infectious Diseases."},{"issue":"7","key":"2026090101164190000_r89","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/JCM.00121-06","article-title":"Sensitivities of 4 new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms","volume":"44","author":"Ly","year":"2006","journal-title":"J Clin Microbiol."},{"issue":"3p2","key":"2026090101164190000_r90","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1423-0410.2009.01272.x","article-title":"Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes","volume":"98","author":"Scheiblauer","year":"2010","journal-title":"Vox Sanguinis."},{"issue":"4","key":"2026090101164190000_r91","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jama.2019.9365","article-title":"Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force statement","volume":"322","author":"USPSTF","year":"2019","journal-title":"JAMA."},{"issue":"11","key":"2026090101164190000_r92","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/00006454-199511000-00001","article-title":"Hepatitis B virus serology in pregnant women: transmittal of results from obstetricians to pediatricians in California","volume":"14","author":"Rosenthal","year":"1995","journal-title":"Pediatr Infect Dis J."},{"key":"2026090101164190000_r93","volume-title":"States Report Hundreds of Medical Errors in Perinatal Hepatitis B Prevention","author":"Anderson","year":"2005"},{"issue":"1","key":"2026090101164190000_r94","doi-asserted-by":"crossref","first-page":"2567043","DOI":"10.1080\/21645515.2025.2567043","article-title":"Healthcare worker perspectives on system-level barriers to hepatitis B birth dose vaccination: an analysis in five urban U.S. hospitals","volume":"21","author":"Shaw","year":"2025","journal-title":"Human Vaccines & Immunotherapeutics."},{"issue":"4","key":"2026090101164190000_r95","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1542\/peds.2009-1831","article-title":"Gaps in hospital policies and practices to prevent perinatal transmission of hepatitis B virus","volume":"125","author":"Willis","year":"2010","journal-title":"Pediatrics."},{"issue":"8219","key":"2026090101164190000_r96","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(81)92877-4","article-title":"Survival of hepatitis B virus after drying and storage for one week","volume":"1","author":"Bond","year":"1981","journal-title":"Lancet."},{"issue":"4","key":"2026090101164190000_r97","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/infdis\/140.4.513","article-title":"Transmission of hepatitis B virus in clinical laboratory areas","volume":"140","author":"Lauer","year":"1979","journal-title":"J Infect Dis."},{"issue":"2","key":"2026090101164190000_r98","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1542\/peds.89.2.269","article-title":"Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees","volume":"89","author":"Hurie","year":"1992","journal-title":"Pediatrics."},{"issue":"6","key":"2026090101164190000_r99","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1542\/peds.96.6.1113","article-title":"Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana","volume":"96","author":"Mahoney","year":"1995","journal-title":"Pediatrics."},{"key":"2026090101164190000_r100","article-title":"Hepatitis B vaccination policies, practices and challenges to achieving hepatitis elimination in the European Union and European Economic Area","author":"ECDC","year":"2025"},{"key":"2026090101164190000_r101","article-title":"Surveillance for acute viral hepatitis\u2014United States, 2007","author":"CDC","year":"2009"},{"key":"2026090101164190000_r102","article-title":"Index of U.S. 2012 surveillance data for viral hepatitis | CDC","author":"CDC","year":"2014"},{"key":"2026090101164190000_r103","article-title":"2016 Surveillance data for viral hepatitis | CDC","author":"CDC","year":"2018"},{"key":"2026090101164190000_r104","article-title":"2020 Viral hepatitis surveillance report","author":"CDC","year":"2022"},{"key":"2026090101164190000_r105","article-title":"MMWR summaries of notifiable diseases","author":"CDC"},{"key":"2026090101164190000_r106","author":"Webinar series - Hepatitis B: education and support for health departments"},{"key":"2026090101164190000_r107","article-title":"Viral hepatitis surveillance reports","author":"CDC","year":"2025"},{"key":"2026090101164190000_r108","article-title":"Recommendation of the Immunization Practices Advisory Committee (ACIP) Postexposure prophylaxis of Hepatitis B","author":"CDC","year":"1984"},{"key":"2026090101164190000_r109","article-title":"Notice to Readers: Recommended Childhood Immunization Schedule\u2014United States, 2002","author":"CDC","year":"2002"},{"issue":"19","key":"2026090101164190000_r110","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1001\/jama.291.19.2351","article-title":"Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage","volume":"291","author":"Luman","year":"2004","journal-title":"JAMA."},{"key":"2026090101164190000_r111","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents","author":"CDC","year":"2005"},{"issue":"1","key":"2026090101164190000_r112","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1542\/peds.2005-2993","article-title":"Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations","volume":"118","author":"Fombonne","year":"2006","journal-title":"Pediatrics."},{"issue":"3","key":"2026090101164190000_r113","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1542\/peds.2004-0434","article-title":"Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data","volume":"114","author":"Parker","year":"2004","journal-title":"Pediatrics."},{"issue":"2","key":"2026090101164190000_r114","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0749-3797(03)00113-2","article-title":"Autism and thimerosal-containing vaccines: lack of consistent evidence for an association","volume":"25","author":"Stehr-Green","year":"2003","journal-title":"Am J Prev Med."},{"issue":"13","key":"2026090101164190000_r115","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMoa071434","article-title":"Early thimerosal exposure and neuropsychological outcomes at 7 to 10\u00a0years","volume":"357","author":"Thompson","year":"2007","journal-title":"N Engl J Med."},{"issue":"12","key":"2026090101164190000_r116","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/pds.3482","article-title":"Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7\u201310\u2009years","volume":"22","author":"Iqbal","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"3","key":"2026090101164190000_r117","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00431-014-2412-5","article-title":"Early exposure to thimerosal-containing vaccines and children\u2019s cognitive development. A 9-year prospective birth cohort study in Poland","volume":"174","author":"Mrozek-Budzyn","year":"2015","journal-title":"Eur J Pediatr."},{"issue":"4","key":"2026090101164190000_r118","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1542\/peds.2010-0309","article-title":"Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism","volume":"126","author":"Price","year":"2010","journal-title":"Pediatrics."},{"issue":"1","key":"2026090101164190000_r119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archgenpsychiatry.2007.1","article-title":"Continuing increases in autism reported to California\u2019s developmental services system: mercury in retrograde","volume":"65","author":"Schechter","year":"2008","journal-title":"Arch Gen Psychiatry."},{"issue":"6","key":"2026090101164190000_r120","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1542\/peds.2009-2489","article-title":"On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes","volume":"125","author":"Smith","year":"2010","journal-title":"Pediatrics."},{"key":"2026090101164190000_r121","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuro.2014.06.007","article-title":"A meta-analysis of the evidence on the impact of prenatal and early infancy exposures to mercury on autism and attention deficit\/hyperactivity disorder in the childhood","volume":"44","author":"Yoshimasu","year":"2014","journal-title":"Neurotoxicology."},{"issue":"1","key":"2026090101164190000_r122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/23744235.2023.2258208","article-title":"Impact of hepatitis B birth dose on immune response in Pakistani children: an open-label, non-inferiority randomized controlled trial, implications for achieving SDG target","volume":"56","author":"Gorar","year":"2024","journal-title":"Infect Dis (Lond)."},{"issue":"33","key":"2026090101164190000_r123","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1016\/j.vaccine.2015.06.081","article-title":"Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers","volume":"33","author":"Kang","year":"2015","journal-title":"Vaccine."},{"issue":"12","key":"2026090101164190000_r124","doi-asserted-by":"crossref","first-page":"e1001774","DOI":"10.1371\/journal.pmed.1001774","article-title":"Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial","volume":"11","author":"Qu","year":"2014","journal-title":"PLoS Med."},{"issue":"4","key":"2026090101164190000_r125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0264-410X(95)98260-H","article-title":"A reduced dose approach to hepatitis B vaccination for low-risk newborns and preschool children","volume":"13","author":"Lee","year":"1995","journal-title":"Vaccine."},{"issue":"3","key":"2026090101164190000_r126","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jiab401","article-title":"Universal infant hepatitis B virus (HBV) vaccination for 35\u00a0years: moving toward the eradication of HBV","volume":"225","author":"Chang","year":"2022","journal-title":"J Infect Dis."},{"issue":"22","key":"2026090101164190000_r127","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1001\/jama.1989.03420220092033","article-title":"Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers","volume":"261","author":"Poovorawan","year":"1989","journal-title":"JAMA."},{"issue":"19","key":"2026090101164190000_r128","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1001\/jama.1987.03390190090026","article-title":"Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission","volume":"257","author":"Stevens","year":"1987","journal-title":"JAMA."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2025-075783\/1926230\/pediatrics.2025075783.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2025-075783\/1926230\/pediatrics.2025075783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:17:03Z","timestamp":1788239823000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/157\/5\/e2025075783\/206357\/Hepatitis-B-Vaccination-at-Birth-Safety"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":128,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,17]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2025-075783","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"e2025075783"}}